Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis

Journal of Infectious Diseases

Volumn 198, Issue 12, 2008, Pages 1842-1850

  Harris, James ^a   Hope, Jayne C ^b   Keane, Joseph ^a  

^a ST JAMES S HOSPITAL   (Ireland)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACROPHAGE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHAGOSOME; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR;

ANTIBODIES, MONOCLONAL; ANTITUBERCULAR AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; PHAGOSOMES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56749153497     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/593174     Document Type: Article

References (46)

1. Lopez Ramirez GM, Rom WN, Ciotoli C, et al. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun 1994; 62:2515-20.
2. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168:4620-7.
3. Dambuza I, Allie N, Fick L, et al. Efficacy of membrane TNF mediated host resistance is dependent on mycobacterial virulence. Tuberculosis (Edinb) 2008; 88:221-34.
4. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998; 161:2636-41.
5. Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-gamma independent manner. Tuberculosis (Edinb) 2002; 82:55-61.
6. Roach TI, Barton CH, Chatterjee D, Blackwell JM. Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. J Immunol 1993; 150:1886-96.
7. Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol 1991; 49:380-7.
8. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J Immunol 1989; 143:2894-9.
9. Keane J, Balcewicz-Sablinska MK, Remold HG, et al. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 1997; 65:298-304.
10. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 2000; 164:2016-20.
11. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162:3504-11.
12. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2:561-72.
13. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69:1847-55.
14. Turner J, Frank AA, Brooks JV, Marietta PM, Orme IM. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 2001; 102:248-53.
15. Jacobs M, Togbe D, Fremond C, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect 2007; 9:623-8.
16. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53:45-53.
17. Grell M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm 1995; 47:8-17.
18. Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003; 33:1-18.
19. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21(Suppl 2):S24-34.
20. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-104.
21. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004; 39:1254-5.
22. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48:2122-7.
23. Hamdi H, Mariette X, Godot V, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006; 8:R114.
24. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006; 194:486-92.
25. Harris J, Schwinn N, Mahoney JA, et al. A vitellogenic-like carboxypeptidase expressed by human macrophages is localized in endoplasmic reticulum and membrane ruffles. Int J Exp Pathol 2006; 87:29-39.
26. Harris J, De Haro SA, Master SS, et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007; 27:505-17.
27. Deretic V, Singh S, Master S, et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defence mechanism. Cell Microbiol 2006; 8:719-27.
28. Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG. Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 1998; 160:1290-6.
29. Via LE, Fratti RA, McFalone M, Pagan-Ramos E, Deretic D, Deretic V. Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci 1998; 111:897-905.
30. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003; 48:1853-7.
31. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48:319-24.
32. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344:1099-100.
33. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44:714-20.
34. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2:602-10.
35. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15:212-22.
36. Emilie D. Effect of TNF antagonists on the T-lymphocyte response. Joint Bone Spine 2007; 74:558-9.
37. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-26.
38. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 2005; 44:157-63.
39. Alexopoulou L, Kranidioti K, Xanthoulea S, et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity. Eur J Immunol 2006; 36:2768-80.
40. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol 2002; 168:3394-401.
41. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175:1111-22.
42. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 2004; 119:753-66.
43. MacMicking JD, Taylor GA, McKinney JD. Immune control of tuberculosis by IFN-gamma-inducible LRG-47. Science 2003; 302:654-9.
44. Sato K, Akaki T, Tomioka H. Differential potentiation of antimycobacterial activity and reactive nitrogen intermediate-producing ability of murine peritoneal macrophages activated by interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha). Clin Exp Immunol 1998; 112:63-8.
45. Plessner HL, Lin PL, Kohno T, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007; 195:1643-50.
46. Marino S, Sud D, Plessner H, et al. Differences in reactivation of tuberculosis induced from anti-TNF treatments are based on bioavailability in granulomatous tissue. PLoS Comput Biol 2007; 3:1909-24.